metastatic urothelial carcinoma Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 1/2 (1)

Interventional (1)

Dragonfly Therapeutics (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadmeasurable disease

I am/have/hadcancer

I am/have/hadBRAF

I am/have/hadtransitional cell carcinoma

I am/have/hadcarcinoma

I am/have/hadmetastatic urothelial carcinoma

I am/have/hadmetastasis

I am/have/hadhair thinning

I am/have/hadneuropathy

I am/have/hadrenal pelvis

I am/have/hadpd-l1

I am/have/hadrenal cell carcinoma

I am/have/hadnon-small cell lung cancer

I am/have/hadcancer treatment

I am/have/hadsmall cell lung cancer

I am/have/hadsolid tumor

I am/have/hadrenal function

I am/have/hadvegf

I am/have/hadlung cancer

I am/have/hadesophageal carcinoma

added new label for I am/have/had

more

I am looking for

I am looking forpembrolizumab

I am looking foradjuvant

I am looking formelanoma

I am looking forgrowth factor

I am looking fornivolumab

I am looking forbraf inhibitor

I am looking forvegf

I am looking forimmunomodulators

I am looking forplatinum-based chemotherapy

I am looking forimmunostimulants

I am looking forvascular endothelial growth factor

I am looking forimmunostimulant

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Phase 1
For Seniors
For adults
Recruiting in 100s
Interventional Study
all
Dermatology
Recruiting

Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications

This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with pembrolizumab.

vegf

measurable disease

melanoma

metastasis

renal cell carcinoma

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2024 All rights reserved.